CTKB

+ Watchlist + Portfolio

Cytek Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.70
52-Week Range: $3.28 – $6.18
Market Cap: $605.72M
P/E (TTM): —
EPS (TTM): -0.63
Dividend Yield: —

Advanced Metrics

Price/Book: 1.88
PEG Ratio: —
Return on Equity: -23.04%
Return on Assets: -6.31%
Gross Margin: 51.88%
Operating Margin: -29.50%
Profit Margin: -38.98%
Current Ratio: 4.48
Debt/Equity: 0.08
Total Debt: $26.46M
Free Cash Flow: $9.30M
Revenue Growth: 5.60%
Earnings Growth: —
Enterprise Value: $375.38M

CTKB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$164.04M	$193.01M	$200.45M	$201.49M
Cost of Revenue	$63.06M	$83.59M	$89.35M	$97.03M
Gross Profit	$100.97M	$109.43M	$111.11M	$104.46M
Research & Development	$34.86M	$44.15M	$39.40M	$36.47M
Selling, General & Admin	$67.92M	$93.12M	$92.23M	$108.38M
Operating Expenses	$102.78M	$137.27M	$131.63M	$144.84M
Operating Income	-$1.80M	-$27.84M	-$20.52M	-$40.38M
EBITDA	$9.49M	-$4.41M	-$10.03M	-$17.39M
Pretax Income	$1.26M	-$15.71M	-$5.70M	-$29.84M
Income Tax	-$1.22M	-$3.56M	$320.00K	$36.70M
Net Income	$2.58M	-$12.15M	-$6.02M	-$66.54M
Diluted EPS	0.02	-0.09	-0.05	-0.52
Diluted Shares	138.56M	130.71M	130.61M	127.75M

CTKB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$296.60M	$167.30M	$98.72M	$90.85M
Receivables	$50.88M	$56.12M	$60.59M	$72.13M
Inventory	$48.15M	$60.88M	$43.89M	$48.43M
Current Assets	$454.02M	$392.06M	$396.45M	$392.00M
Total Assets	$519.48M	$494.46M	$499.50M	$461.54M
Current Liabilities	$49.04M	$56.23M	$67.66M	$77.80M
Long-Term Debt	$2.27M	$1.65M	$1.05M	$525.00K
Total Debt	$18.09M	$14.14M	$17.02M	$23.74M
Total Liabilities	$93.93M	$101.39M	$103.76M	$119.80M
Retained Earnings	-$17.03M	-$29.18M	-$35.20M	-$101.74M
Shareholders' Equity	$425.30M	$393.06M	$395.74M	$341.74M
Working Capital	$404.98M	$335.83M	$328.78M	$314.19M

CTKB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.23M	$5.28M	$25.38M	-$4.69M
Capital Expenditure	-$9.87M	-$4.83M	-$3.73M	-$4.19M
Free Cash Flow	-$22.10M	$454.00K	$21.65M	-$8.88M
Depreciation & Amortisation	$5.66M	$9.23M	$10.49M	$11.97M
Stock-Based Compensation	$16.59M	$22.05M	$26.85M	$24.59M
Investing Cash Flow	-$55.91M	-$93.89M	-$82.97M	$10.12M
Financing Cash Flow	$5.51M	-$41.81M	-$15.82M	-$13.43M
Share Repurchases	$0.00	-$44.15M	-$21.61M	-$15.07M
Net Change in Cash	-$62.63M	-$130.43M	-$73.42M	-$8.00M

CTKB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$41.46M	$45.60M	$52.29M	$62.14M	$44.13M
Cost of Revenue	$21.30M	$21.73M	$24.74M	$29.26M	$22.88M
Gross Profit	$20.16M	$23.87M	$27.55M	$32.88M	$21.25M
Research & Development	$9.72M	$8.83M	$8.96M	$8.96M	$9.60M
Selling, General & Admin	$25.41M	$25.66M	$27.79M	$29.52M	$30.11M
Operating Expenses	$35.13M	$34.49M	$36.74M	$38.48M	$39.72M
Operating Income	-$14.97M	-$10.62M	-$9.19M	-$5.59M	-$18.46M
EBITDA	-$8.09M	-$3.37M	-$4.21M	-$1.71M	-$14.30M
Pretax Income	-$11.27M	-$6.78M	-$7.77M	-$4.03M	-$17.37M
Income Tax	$136.00K	-$1.19M	-$2.29M	$40.05M	$1.49M
Net Income	-$11.40M	-$5.58M	-$5.48M	-$44.08M	-$18.87M
Diluted EPS	-0.09	-0.04	-0.04	-0.34	-0.15
Diluted Shares	128.34M	126.93M	127.55M	128.17M	128.70M

CTKB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$95.30M	$75.47M	$93.28M	$90.85M	$65.67M
Receivables	$55.21M	$56.67M	$61.67M	$72.13M	$56.48M
Inventory	$45.35M	$49.49M	$51.65M	$48.43M	$49.79M
Current Assets	$380.50M	$382.82M	$388.49M	$392.00M	$379.30M
Total Assets	$482.60M	$493.32M	$494.92M	$461.54M	$449.11M
Current Liabilities	$67.69M	$73.27M	$75.21M	$77.80M	$80.94M
Long-Term Debt	$918.00K	$791.00K	$655.00K	$525.00K	$386.00K
Total Debt	$15.90M	$23.68M	$24.83M	$23.74M	$27.48M
Total Liabilities	$102.97M	$115.76M	$116.35M	$119.80M	$121.47M
Retained Earnings	-$46.60M	-$52.18M	-$57.66M	-$101.74M	-$120.60M
Shareholders' Equity	$379.62M	$377.56M	$378.57M	$341.74M	$327.64M
Working Capital	$312.81M	$309.56M	$313.28M	$314.19M	$298.37M

CTKB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$125.00K	$108.00K	-$3.90M	-$771.00K	-$2.74M
Capital Expenditure	-$851.00K	-$1.65M	-$655.00K	-$1.03M	-$2.20M
Free Cash Flow	-$976.00K	-$1.54M	-$4.55M	-$1.80M	-$4.94M
Depreciation & Amortisation	$2.88M	$2.99M	$3.06M	$3.04M	$2.81M
Stock-Based Compensation	$6.63M	$6.79M	$5.64M	$5.53M	$4.86M
Investing Cash Flow	$9.45M	-$16.41M	$18.92M	-$1.84M	-$27.08M
Financing Cash Flow	-$11.54M	-$2.60M	$1.94M	-$1.23M	$3.98M
Share Repurchases	-$10.63M	-$4.51M	$29.00K	$34.00K	$0.00
Net Change in Cash	-$2.22M	-$18.91M	$16.96M	-$3.84M	-$25.83M

Market Snapshot

About

Cytek Biosciences, Inc. is a cell analysis solutions company headquartered in Fremont, California, that develops and manufactures advanced flow cytometry platforms for biomedical research and clinical applications. The company's proprietary Full Spectrum Profiling technology enables researchers to analyze more cellular characteristics simultaneously than traditional flow cytometry systems. Cytek's flagship products include the Aurora and Northern Lights systems, which serve academic institutions, pharmaceutical and biotechnology companies, and clinical laboratories worldwide. The company's technology is used in immunology, oncology, stem cell research, and other fields requiring detailed cellular analysis.